Fufang Xueshuantong （FXT） is a well-known Chinese herbal formula which has been used to treat car- diovascular and ophthalmic diseases, especially diabetic retinopathy. Panax notoginseng （Burkill） F.H. Chen （PN）...Fufang Xueshuantong （FXT） is a well-known Chinese herbal formula which has been used to treat car- diovascular and ophthalmic diseases, especially diabetic retinopathy. Panax notoginseng （Burkill） F.H. Chen （PN） is the main herb of FXT, whose major bioactive constituents are ginsenosides. However, the scientific basis of the compatibility of FXT is still ambiguous. The present study investigated the scientific basis of the compatibility of FXT by comparing the pharmacokinetics of marker compounds after oral administrations of PN and FXT. A high performance liquid chromatography-electrospray ionization tandem mass spectrometry （HPLC-ESI-MS/MS） method was devel- oped for simultaneous detection of notoginsenoside R1 （NR1）, ginsenoside Rgl （GRgl）, and ginsenoside Rbl （GRbl） in rat plasma. The pharmacokinetic studies of FXT and PN were performed using the established method with the pharmacokinetic parameters being determined by non-compartmental analysis. The results showed that the phar- macokinetic parameters （maximum concentration, area under the curve （AUC0-t）, clearance, and mean residence time） of NR1, GRgl, and GRbl were significantly different after oral administration of FXT （P〈0.05） compared with PN. The AUO0-t values of GRgl and GRbl were 1.7- and 3.4-fold greater, respectively, in FXT than in PN. The compatible herbs of FXT could prolong the retention time and increase the systemic exposure of NR1, GRgl, and GRbl compared with PN in vivo, providing some scientific basis for the compatibility and clinical use of FXT.展开更多
Objective：To establish a retinal vein occlusion（RVO） animal model and observe the therapeutic effect of a Chinese herbal composition（Fufang Xueshuantong Capsule,复方血栓通胶囊,FXC） in ischemic retinal disease.Met...Objective：To establish a retinal vein occlusion（RVO） animal model and observe the therapeutic effect of a Chinese herbal composition（Fufang Xueshuantong Capsule,复方血栓通胶囊,FXC） in ischemic retinal disease.Methods：Fifteen adult male Sprague-Dawley rats underwent laser photothrombosis to induce RVO on their right eyes and were subsequently randomized to receive FXC（the intervention group,n=7） or placebo treatment（the control group,n=8）.Fundus fluorescein angiography was performed after 2,4 and 8 weeks of treatment.Real-time reverse transcription-PCR was used to quantify the mRNA expression of vascular endothelial growth factor（VEGF） and stromal cell-derived factor-1（SDF-1）.The main outcomes were the mRNA copies of VEGF and SDF-1 and the counts of RVO signs.Results：Laser photothrombosis procedure induced typical lesions of RVO,including hemorrhage,leakage,retinal detachment,capillary non-perfusion,filling defect of retinal vessels,and lateral circulation/dilation of small vessels.The retinal lesions were associated with an increased expression of VEGF（P0.05）.No significant change of SDF-1 expression was noticed.Compared with the control group,the intervention group had numerically fewer RVO lesions at week 2（1.71±0.76 vs.3.50±1.51,t=-2.82,P0.05）.The benefit of intervention remained at weeks 4 and 8.Conclusions：A rat model of laser photothrombosis-induced RVO was established and an increase in the VEGF expression was observed in the retinal lesion.The FXC had therapeutic benefit in improving retinal lesions in the rat model of RVO.展开更多
目的:系统评价复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞的有效性。方法:计算机检索PubMed、Embase、Web of Science、CNKI、万方和维普数据库等,搜集关于复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞的随机对照试验(RC...目的:系统评价复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞的有效性。方法:计算机检索PubMed、Embase、Web of Science、CNKI、万方和维普数据库等,搜集关于复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞的随机对照试验(RCT),检索时限均从建库至2023年5月25日。采用RoB2.0对纳入研究进行偏倚风险评估,采用RevMan5.4软件进行Meta分析。结果:共纳入8研究,包括702名患者。结果显示,与对照组相比,联合治疗组可以提高患者综合疗效有效率[OR=1.23,CI(1.16,1.32),P<0.00001],在血液流变学指标方面,全血粘度[MD=-0.76,95%CI(-1.32,-0.20),P=0.008]、血浆粘度[MD=-0.37,95%CI(-0.47,-0.27),P<0.00001]、红细胞聚集指数[MD=-0.96,95%CI(-1.09,-0.84),P<0.00001]、红细胞比容[MD=-0.09,95%CI(-0.11,-0.07),P<0.00001]、纤维蛋白原[MD=-0.62,95%CI(-0.90,-0.33),P<0.00001]。结论:Meta分析结果表明,复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞可能改善血液流变学指标,能明显提升综合疗效有效率。但由于原始文献质量较低,分析结果具有一定限制性,故上述结论尚待更多高质量研究予以验证。展开更多
基金supported by the Ministry of Science and Technology of China(No.2011ZX09201-201-22)
文摘Fufang Xueshuantong （FXT） is a well-known Chinese herbal formula which has been used to treat car- diovascular and ophthalmic diseases, especially diabetic retinopathy. Panax notoginseng （Burkill） F.H. Chen （PN） is the main herb of FXT, whose major bioactive constituents are ginsenosides. However, the scientific basis of the compatibility of FXT is still ambiguous. The present study investigated the scientific basis of the compatibility of FXT by comparing the pharmacokinetics of marker compounds after oral administrations of PN and FXT. A high performance liquid chromatography-electrospray ionization tandem mass spectrometry （HPLC-ESI-MS/MS） method was devel- oped for simultaneous detection of notoginsenoside R1 （NR1）, ginsenoside Rgl （GRgl）, and ginsenoside Rbl （GRbl） in rat plasma. The pharmacokinetic studies of FXT and PN were performed using the established method with the pharmacokinetic parameters being determined by non-compartmental analysis. The results showed that the phar- macokinetic parameters （maximum concentration, area under the curve （AUC0-t）, clearance, and mean residence time） of NR1, GRgl, and GRbl were significantly different after oral administration of FXT （P〈0.05） compared with PN. The AUO0-t values of GRgl and GRbl were 1.7- and 3.4-fold greater, respectively, in FXT than in PN. The compatible herbs of FXT could prolong the retention time and increase the systemic exposure of NR1, GRgl, and GRbl compared with PN in vivo, providing some scientific basis for the compatibility and clinical use of FXT.
基金Supported in part by Science and Technology Commission of Shanghai Municipality(Grant No.074119510)
文摘Objective：To establish a retinal vein occlusion（RVO） animal model and observe the therapeutic effect of a Chinese herbal composition（Fufang Xueshuantong Capsule,复方血栓通胶囊,FXC） in ischemic retinal disease.Methods：Fifteen adult male Sprague-Dawley rats underwent laser photothrombosis to induce RVO on their right eyes and were subsequently randomized to receive FXC（the intervention group,n=7） or placebo treatment（the control group,n=8）.Fundus fluorescein angiography was performed after 2,4 and 8 weeks of treatment.Real-time reverse transcription-PCR was used to quantify the mRNA expression of vascular endothelial growth factor（VEGF） and stromal cell-derived factor-1（SDF-1）.The main outcomes were the mRNA copies of VEGF and SDF-1 and the counts of RVO signs.Results：Laser photothrombosis procedure induced typical lesions of RVO,including hemorrhage,leakage,retinal detachment,capillary non-perfusion,filling defect of retinal vessels,and lateral circulation/dilation of small vessels.The retinal lesions were associated with an increased expression of VEGF（P0.05）.No significant change of SDF-1 expression was noticed.Compared with the control group,the intervention group had numerically fewer RVO lesions at week 2（1.71±0.76 vs.3.50±1.51,t=-2.82,P0.05）.The benefit of intervention remained at weeks 4 and 8.Conclusions：A rat model of laser photothrombosis-induced RVO was established and an increase in the VEGF expression was observed in the retinal lesion.The FXC had therapeutic benefit in improving retinal lesions in the rat model of RVO.
文摘目的:系统评价复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞的有效性。方法:计算机检索PubMed、Embase、Web of Science、CNKI、万方和维普数据库等,搜集关于复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞的随机对照试验(RCT),检索时限均从建库至2023年5月25日。采用RoB2.0对纳入研究进行偏倚风险评估,采用RevMan5.4软件进行Meta分析。结果:共纳入8研究,包括702名患者。结果显示,与对照组相比,联合治疗组可以提高患者综合疗效有效率[OR=1.23,CI(1.16,1.32),P<0.00001],在血液流变学指标方面,全血粘度[MD=-0.76,95%CI(-1.32,-0.20),P=0.008]、血浆粘度[MD=-0.37,95%CI(-0.47,-0.27),P<0.00001]、红细胞聚集指数[MD=-0.96,95%CI(-1.09,-0.84),P<0.00001]、红细胞比容[MD=-0.09,95%CI(-0.11,-0.07),P<0.00001]、纤维蛋白原[MD=-0.62,95%CI(-0.90,-0.33),P<0.00001]。结论:Meta分析结果表明,复方血栓通联合复方樟柳碱注射液治疗视网膜静脉阻塞可能改善血液流变学指标,能明显提升综合疗效有效率。但由于原始文献质量较低,分析结果具有一定限制性,故上述结论尚待更多高质量研究予以验证。
